Widely read:
AI-generated image
Leadership reshuffles, FDA approvals, dividend bombs, and job cuts—India's most talked-about stocks are buzzing for all the right (and wrong) reasons. From TCS's hush-hush increment freeze to Paytm's regulatory déjà vu, here's the latest heat check on the headlines.
Suppose you eavesdrop on the stock market this week. In that case, you'll hear some unusually juicy gossip—TCS is holding back pay hikes (but generously doling out dividends), Biocon's breaking into new pharma territory overseas, and Sun Pharma just dodged a legal landmine to launch a new drug. Meanwhile, BHEL wandered into fertiliser factories, HDFC Bank remains everyone's favourite poster child, and Asian Paints might be brushing up for a rebound. Tata Steel is trimming jobs in Europe, Adani is plotting spin-offs, Coal India is making your savings account jealous with its dividend yield, and Paytm... well, Paytm's back in trouble (again). It's a week where the balance sheets are as lively as the boardrooms, and this roundup gives you the full download—with all the sizzle, speculation, and stock ratings you need.
TCS (Tata Consultancy Services)
Price (INR): Rs 3,231.50 (April 11, 2025)
52-Week Range (INR): Rs 3,056.05 - Rs 4,592.25
Value Research Rating: ★★★★ (4-star)
Quality - 10/10
Growth - 6/10
Valuation - 5/10
Momentum - 1/10
TCS announced the appointment of Aarthi Subramanian as Executive Director and COO, effective May 2025. In parallel, the company deferred April salary hikes due to global economic uncertainty but will honour variable pay and plans to hire around 42,000 freshers in FY26. Additionally, TCS declared a Rs 45,600 crore dividend payout for FY25, keeping investor attention locked in.
Price (INR): Rs 316.55
52-Week Range (INR): Rs 259.85 - Rs 404.70
Value Research Rating: ★★★
Quality - 2/10
Growth - 7/10
Valuation - 5/10
Momentum - 8/10
Biocon's biotech subsidiary received USFDA approval for Jobevne, a biosimilar bevacizumab. This strengthens Biocon's US oncology portfolio. Earlier, the company also resolved patent issues, enabling the US launch of its Stelara biosimilar. These developments support Biocon's global growth strategy through biosimilars.
BHEL (Bharat Heavy Electricals)
Price (INR): Rs 212.97
52-Week Range (INR): Rs 176.00 - Rs 335.35
Value Research Ratings: ★
Quality - 1/10
Growth - 5/10
Valuation - 1/10
Momentum - 4/10
BHEL entered a 10-year agreement with Italy's Nuovo Pignone to upgrade compressors in India's ageing fertiliser plants. The collaboration could capture up to 50per cent of market share in this niche, helping BHEL diversify beyond its traditional power equipment base.
Price (INR): Rs 1,687.55
52-Week Range (INR): Rs 1,377.20 - Rs 1,960.35
Value Research Ratings: ★★★★
Quality - 8/10
Growth - 8/10
Valuation - 4/10
Momentum - 6/10
Sun Pharma received a major legal boost after a US court lifted an injunction that had delayed the launch of its alopecia drug LEQSELVI. With litigation resolved, Sun can now capitalise on US market opportunities. The company also issued a healthy interim dividend earlier in the year.
Price (INR): Rs 1,806.75
52-Week Range (INR): Rs 1,426.80 - Rs 1,880.00
Value Research Ratings: ★★★★★
Quality - 9/10
Growth - 7/10
Valuation - 6/10
Momentum - 9/10
HDFC Bank remains a top analyst pick after its merger with HDFC Ltd. The bank is expanding its deposit base and improving its credit-deposit ratio. Analysts forecast margin improvement and a target price of Rs 2,350, highlighting its long-term potential and stability.
Price (INR): Rs 2,393.60
52-Week Range (INR): Rs 2,124.75 - Rs 3,394.90
Value Research Ratings: ★★★
Quality - 10/10
Growth - 7/10
Valuation - 4/10
Momentum - 1/10
Following a price dip, Asian Paints has appeared in several "Buy" calls. Technical charts suggest bullish momentum, and analysts anticipate a near-term rebound. The company continues to lead with strong fundamentals and consistent performance.
Price (INR): Rs 133.42
52-Week Range (INR): Rs 122.62 - Rs 184.60
Value Research Ratings: ★★
Quality - 3/10
Growth - 4/10
Valuation - 4/10
Momentum - 5/10
Tata Steel announced 1,600 job cuts in the Netherlands to improve efficiency in its European operations. This is part of a broader restructuring and sustainability initiative. While reception was mixed, the move is expected to help boost profitability.
Price (INR): Rs 2,321.40
52-Week Range (INR): Rs 2,025.00 - Rs 3,743.90
Value Research Ratings: ★★
Quality - 3/10
Growth - 6/10
Valuation - 4/10
Momentum - 3/10
Adani Enterprises is seen as a high-risk, high-reward bet for 2025. The group aims to unlock shareholder value with plans to spin off airport and road businesses. Analysts expect a revival in fortunes post-Hindenburg, especially with improved cash flow and lower debt levels.
Most Recent Price (INR): Rs 392.10
52-Week Range (INR): Rs 349.25 - Rs 543.55
Value Research Ratings: ★★★★
Quality - 10/10
Growth - 5/10
Valuation - 8/10
Momentum - 2/10
Coal India has attracted investor interest due to its 7per cent dividend yield and consistent earnings. The PSU is also diversifying into renewables and metals while benefitting from strong domestic coal demand. It remains a favourite for value-focused investors.
Price (INR): Rs 840.70
52-Week Range (INR): Rs 310.00 - Rs 1,062.95
Value Research Ratings: ★★★
Quality - 3/10
Growth - 7/10
Valuation - 2/10
Momentum - 10/10
Paytm continues to draw attention amid regulatory issues and analyst downgrades. Despite operating profit in Q3 FY25, concerns remain around its business model. Enforcement Directorate notices and RBI curbs on its Payments Bank have spooked sentiment. Analysts remain cautious, with some recommending a sell.
Also read: 10 small-cap stocks everyone's watching
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
